ACS chemical neuroscience molecule spotlight on Sabril

Research output: Contribution to journalShort surveypeer-review

2 Scopus citations


Sabril (vigabatrin) oral solution was approved by the FDA on August 21st, 2009 for treatment of infantile spasms in children ages 1 month to 2 years and complex partial seizures in adults (tablets).

Original languageEnglish (US)
Pages (from-to)475
Number of pages1
JournalACS Chemical Neuroscience
Issue number7
StatePublished - Jul 21 2010
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology


Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on Sabril'. Together they form a unique fingerprint.

Cite this